Key Segmentation
By Product
-
Assay Kits & Reagents
-
Instruments
By Technology
-
Flow Cytometry
-
Polymerase Chain Reaction (PCR)
-
Next-Generation Sequencing (NGS)
-
Others
By Cancer Type
-
Hematological Malignancies
-
Solid Tumors
-
Multiple Myeloma
-
Others
By End Use
-
Hospitals and Specialty Clinics
-
Diagnostic Laboratories
-
Academic and Research Institutes
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Flow Cytometry dominated with approximately 40% share in 2025.
North America dominated with approximately 39.9% of revenues in 2025.
Precision oncology integration of MRD status into haematological malignancy treatment guidelines creating structured clinical adoption.
The market was valued at USD 2.69 Billion in 2025.
The market is expected to grow at a CAGR of 11.50% from 2026 to 2035.